VSTM
Verastem, Inc. NASDAQ Listed Jan 27, 2012$5.67
Mkt Cap $393.0M
52w Low $4.01
22.9% of range
52w High $11.25
50d MA $5.75
200d MA $7.50
P/E (TTM)
-1.9x
EV/EBITDA
-2.4x
P/B
7.1x
Debt/Equity
1.3x
ROE
-366.2%
P/FCF
-3.9x
RSI (14)
—
ATR (14)
—
Beta
0.43
50d MA
$5.75
200d MA
$7.50
Avg Volume
1.9M
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
117 Kendrick Street · Needham, MA 02494 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.46 | -0.37 | +19.6% | 5.66 | -3.7% | -13.6% | — | — | — | — | — |
| Mar 4, 2026 | AMC | -0.49 | -0.39 | +20.4% | 5.81 | +2.4% | +5.9% | +9.8% | +8.4% | +10.0% | +6.5% | — |
| Nov 4, 2025 | AMC | -0.51 | -1.35 | -164.7% | 7.91 | +2.4% | +3.2% | +0.3% | +2.0% | +4.3% | +6.8% | — |
| Aug 7, 2025 | AMC | -0.85 | -0.39 | +54.1% | 5.62 | -0.4% | +19.9% | +37.0% | +46.1% | +42.7% | +37.5% | — |
| May 13, 2025 | AMC | -0.72 | -0.96 | -33.3% | 7.46 | -0.3% | -4.4% | +6.3% | +1.7% | +3.9% | +7.6% | — |
| Mar 20, 2025 | AMC | -0.81 | -1.33 | -64.2% | 6.82 | -1.6% | -2.5% | +0.9% | -3.7% | -6.2% | -1.3% | — |
| Nov 6, 2024 | AMC | -0.71 | -0.60 | +15.5% | 3.87 | -3.9% | -7.0% | +2.1% | +15.2% | +13.7% | +5.9% | — |
| Aug 8, 2024 | AMC | -1.06 | -0.31 | +70.8% | 2.24 | +6.2% | +4.9% | +3.6% | +11.2% | +1.3% | +4.0% | — |
| May 9, 2024 | AMC | -1.16 | -1.26 | -8.6% | 11.92 | -1.4% | -0.6% | +0.8% | +10.4% | +10.1% | +1.8% | — |
| Mar 14, 2024 | AMC | -0.82 | -1.02 | -24.4% | 10.50 | -4.9% | +4.8% | +1.1% | +7.7% | +12.3% | +13.6% | — |
| Nov 8, 2023 | AMC | -0.92 | -0.75 | +18.5% | 7.07 | -1.0% | -5.7% | -9.8% | -9.8% | -11.9% | -13.2% | — |
| Aug 8, 2023 | AMC | -1.13 | -1.37 | -21.2% | 10.03 | +3.7% | -0.3% | -2.1% | -2.2% | -5.0% | -4.8% | — |
| May 9, 2023 | AMC | -1.08 | -0.96 | +11.1% | 5.16 | -2.3% | +0.0% | -4.7% | -7.0% | -2.3% | -2.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23 | BTIG | Maintains | Buy → Buy | — | $6.07 | $6.09 | +0.3% | +2.6% | -2.6% | -8.7% | -10.0% | -11.0% |
| Apr 20 | BTIG | Maintains | Buy → Buy | — | $6.58 | $6.60 | +0.3% | -0.9% | -8.1% | -7.8% | -5.3% | -10.2% |
| Apr 10 | BTIG | Maintains | Buy → Buy | — | $5.59 | $5.58 | -0.2% | -5.0% | +1.3% | +9.8% | +13.2% | +13.4% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.59 | $5.58 | -0.2% | -5.0% | +1.3% | +9.8% | +13.2% | +13.4% |
| Sep 9 | BTIG | Maintains | Buy → Buy | — | $10.23 | $10.16 | -0.7% | -3.0% | -3.4% | -8.6% | -5.0% | -4.0% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $5.62 | $5.60 | -0.4% | +19.9% | +37.0% | +46.1% | +42.7% | +37.5% |
| Jun 25 | RBC Capital | Maintains | Outperform → Outperform | — | $4.56 | $4.52 | -0.9% | -5.7% | -8.8% | -9.0% | -9.0% | -5.9% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.94 | $7.15 | +3.0% | +3.3% | +5.0% | +7.5% | +2.7% | +14.3% |
| Apr 9 | Mizuho | Maintains | Outperform → Outperform | — | $4.64 | $4.60 | -0.9% | +13.8% | -2.6% | +0.0% | +3.0% | +3.7% |
| Mar 24 | Guggenheim | Maintains | Buy → Buy | — | $6.65 | $7.06 | +6.2% | +3.5% | -1.2% | -3.8% | +1.2% | -6.9% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.65 | $7.06 | +6.2% | +3.5% | -1.2% | -3.8% | +1.2% | -6.9% |
| Mar 21 | RBC Capital | Maintains | Outperform → Outperform | — | $6.82 | $6.71 | -1.6% | -2.5% | +0.9% | -3.7% | -6.2% | -1.3% |
| Jan 31 | B. Riley Securities | Maintains | Buy → Buy | — | $6.22 | $6.32 | +1.6% | -2.3% | -8.2% | -5.6% | -4.3% | -2.1% |
| Jan 24 | Guggenheim | Maintains | Buy → Buy | — | $5.59 | $5.61 | +0.4% | +5.9% | +1.8% | +4.1% | +7.9% | +11.3% |
| Jan 7 | RBC Capital | Maintains | Outperform → Outperform | — | $6.72 | $6.69 | -0.4% | -2.7% | -12.2% | -14.7% | -20.5% | -25.0% |
| Dec 19 | Mizuho | Maintains | Outperform → Outperform | — | $4.26 | $4.46 | +4.7% | +4.2% | -1.6% | -7.0% | -8.5% | -7.5% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.26 | $4.46 | +4.7% | +4.2% | -1.6% | -7.0% | -8.5% | -7.5% |
| Aug 13 | Truist | Maintains | Buy → Buy | — | $2.32 | $2.33 | +0.4% | +7.3% | -2.2% | +0.4% | -0.9% | +7.3% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.35 | $2.35 | +0.0% | -1.3% | +6.0% | -3.4% | -0.9% | -2.1% |
| Aug 9 | RBC Capital | Maintains | Outperform → Outperform | — | $2.24 | $2.38 | +6.2% | +4.9% | +3.6% | +11.2% | +1.3% | +4.0% |
| Jul 24 | B. Riley Securities | Maintains | Buy → Buy | — | $3.59 | $2.72 | -24.2% | -17.5% | -17.3% | -17.5% | -23.7% | -25.6% |
| Jul 8 | Truist | Maintains | Buy → Buy | — | $2.74 | $2.70 | -1.5% | -4.7% | +1.8% | -0.4% | +8.8% | +22.6% |
| May 29 | Alliance Global Partners | Maintains | Buy → Buy | — | $4.02 | $4.00 | -0.5% | -0.5% | -0.7% | -1.5% | -2.0% | -8.5% |
| May 28 | RBC Capital | Maintains | Outperform → Outperform | — | $4.12 | $4.49 | +9.0% | -2.4% | -2.9% | -3.2% | -3.9% | -4.4% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.12 | $4.49 | +9.0% | -2.4% | -2.9% | -3.2% | -3.9% | -4.4% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.85 | $11.81 | -0.3% | +1.4% | +11.1% | +10.7% | +2.4% | -3.0% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.62 | $10.46 | -1.5% | +6.5% | +11.0% | +12.3% | +13.4% | +8.6% |
| Mar 15 | RBC Capital | Maintains | Outperform → Outperform | — | $10.50 | $9.99 | -4.9% | +4.8% | +1.1% | +7.7% | +12.3% | +13.6% |
| Nov 15 | Truist | Maintains | Buy → Buy | — | $6.23 | $6.44 | +3.4% | -1.4% | -2.9% | +1.6% | +3.5% | +0.8% |
| Sep 29 | B. Riley Securities | Maintains | Buy → Buy | — | $8.32 | $8.46 | +1.7% | -2.3% | -5.8% | -5.0% | -11.1% | -6.9% |
| Aug 29 | Mizuho | Maintains | Buy → Buy | — | $9.98 | $9.93 | -0.5% | -1.8% | +0.0% | -2.2% | -1.2% | -1.8% |
| Aug 9 | RBC Capital | Maintains | Outperform → Outperform | — | $10.03 | $10.40 | +3.7% | -0.3% | -2.1% | -2.2% | -5.0% | -4.8% |
| Jul 11 | Truist | Maintains | Buy → Buy | — | $8.76 | $8.70 | -0.7% | +4.6% | +3.3% | +3.2% | +3.7% | +3.3% |
| Jul 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.88 | $7.93 | +0.6% | +1.0% | +1.5% | +11.2% | +16.2% | +14.8% |
| Jul 3 | RBC Capital | Maintains | Outperform → Outperform | — | $7.44 | $7.37 | -0.9% | +4.2% | +5.9% | +7.0% | +7.5% | +17.7% |
| Jun 27 | Truist | Maintains | Buy → Buy | — | $8.55 | $8.44 | -1.3% | -5.7% | -17.0% | -11.2% | -13.0% | -9.4% |
| Jun 23 | Truist | Maintains | Buy → Buy | — | $9.25 | $9.24 | -0.1% | -5.2% | -7.6% | -12.9% | -23.2% | -17.9% |
| Jun 15 | Mizuho | Upgrade | Neutral → Buy | — | $9.32 | $11.12 | +19.3% | +16.1% | +10.3% | +5.3% | +4.3% | -0.8% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.16 | $5.04 | -2.3% | +0.0% | -4.7% | -7.0% | -2.3% | -2.3% |
| Mar 30 | Mizuho | Maintains | Neutral → Neutral | — | $5.40 | $5.40 | +0.0% | -11.1% | -6.7% | -13.3% | -22.2% | -6.7% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.16 | $5.40 | +4.7% | +0.0% | +4.7% | +7.0% | +4.7% | +4.7% |
| Mar 15 | RBC Capital | Maintains | Outperform → Outperform | — | $5.16 | $5.40 | +4.7% | +0.0% | +4.7% | +7.0% | +4.7% | +4.7% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.68 | $4.68 | +0.0% | +0.0% | +2.6% | -2.6% | +5.1% | +7.7% |
| Oct 5 | BTIG | Maintains | Buy → Buy | — | $6.84 | $6.96 | +1.8% | -7.0% | -7.0% | -14.0% | -15.8% | -21.1% |
| Apr 14 | RBC Capital | Maintains | Outperform → Outperform | — | $18.36 | $19.08 | +3.9% | +15.7% | +19.6% | +8.5% | +10.5% | -1.3% |
| Mar 9 | Truist | Maintains | Buy → Buy | — | $13.44 | $14.76 | +9.8% | +23.2% | +17.0% | +25.9% | +7.1% | +4.5% |
| Jul 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.40 | $41.88 | +1.2% | +6.7% | +3.5% | +0.9% | -4.1% | -3.8% |
| Jul 1 | Alliance Global Partners | Maintains | Buy → Buy | — | $48.84 | $49.68 | +1.7% | +0.0% | -3.7% | -3.2% | -9.6% | -9.8% |
| May 24 | BTIG | Upgrade | Neutral → Buy | — | $38.28 | $39.36 | +2.8% | +24.8% | +21.3% | +26.0% | +25.4% | +21.3% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.60 | $34.80 | +3.6% | +0.0% | +5.0% | +5.0% | +7.9% | +11.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Paterson DanDir/Off | President and CEO | Sell | 806 | $5.82 | $5K | 612,113 | -5.82% | — |
8-K · 7.01
! Medium
Verastem, Inc. -- 8-K 7.01: Regulation FD Disclosure
Verastem updated its corporate presentation, providing investors with refreshed company information and strategic messaging available for review on its website.
Mar 4
8-K · 7.01
! Medium
Verastem, Inc. -- 8-K 7.01: Regulation FD Disclosure
Verastem's Regulation FD disclosure likely signals material non-public information now being shared publicly, which could significantly impact stock price through investor repricing of company prospects or competitive positioning.
Feb 4
Data updated apr 27, 2026 8:20am
· Source: massive.com